Does the media prefer INSP or DCTH?

In the previous week, Inspire Medical Systems had 6 more articles in the media than Delcath Systems. MarketBeat recorded 7 mentions for Inspire Medical Systems and 1 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.11 beat Delcath Systems' score of -0.07 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ESTA or DCTH?

In the previous week, Establishment Labs and Establishment Labs both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.67 beat Delcath Systems' score of -0.07 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BFLY or DCTH?

In the previous week, Butterfly Network had 7 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Butterfly Network and 1 mentions for Delcath Systems. Butterfly Network's average media sentiment score of 0.50 beat Delcath Systems' score of -0.07 indicating that Butterfly Network is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NVCR or DCTH more profitable?

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Delcath Systems 0.56% 0.46% 0.42%

Does the media favor NVCR or DCTH?

In the previous week, NovoCure had 3 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for NovoCure and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of -0.07 beat NovoCure's score of -0.27 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LMAT or DCTH?

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.63 beat Delcath Systems' score of -0.07 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Delcath Systems (DCTH) Competitors

$16.11 -0.14 (-0.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.05 -0.06 (-0.37%)

As of 09/18/2026 07:39 PM Eastern

Compare

DCTH vs. INSP, ESTA, BFLY, NVCR, and LMAT

Should you buy Delcath Systems stock or one of its competitors? Delcath Systems's main competitors and comparable companies include Inspire Medical Systems (INSP), Establishment Labs (ESTA), Butterfly Network (BFLY), NovoCure (NVCR), and LeMaitre Vascular (LMAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Delcath Systems compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inspire Medical Systems has higher revenue and earnings than Delcath Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.44	$145.42M	$4.62	16.63
Delcath Systems	$85.23M	6.56	$2.70M	$0.01	1,611.00

Inspire Medical Systems has a net margin of 15.03% compared to Delcath Systems' net margin of 0.56%. Inspire Medical Systems' return on equity of 8.64% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
Delcath Systems	0.56%	0.46%	0.42%

Inspire Medical Systems has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Inspire Medical Systems currently has a consensus price target of $66.50, indicating a potential downside of 13.47%. Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Inspire Medical Systems had 6 more articles in the media than Delcath Systems. MarketBeat recorded 7 mentions for Inspire Medical Systems and 1 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.11 beat Delcath Systems' score of -0.07 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inspire Medical Systems beats Delcath Systems on 11 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Delcath Systems has a net margin of 0.56% compared to Establishment Labs' net margin of -15.82%. Delcath Systems' return on equity of 0.46% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Delcath Systems	0.56%	0.46%	0.42%

Delcath Systems has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.78	-$51.06M	-$1.31	N/A
Delcath Systems	$85.23M	6.56	$2.70M	$0.01	1,611.00

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Establishment Labs and Establishment Labs both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.67 beat Delcath Systems' score of -0.07 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Establishment Labs presently has a consensus target price of $100.25, suggesting a potential upside of 44.66%. Delcath Systems has a consensus target price of $23.17, suggesting a potential upside of 43.80%. Given Establishment Labs' higher possible upside, equities research analysts plainly believe Establishment Labs is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Delcath Systems beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Delcath Systems has a net margin of 0.56% compared to Butterfly Network's net margin of -66.74%. Delcath Systems' return on equity of 0.46% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
Delcath Systems	0.56%	0.46%	0.42%

Delcath Systems has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	21.54	-$77.06M	-$0.29	N/A
Delcath Systems	$85.23M	6.56	$2.70M	$0.01	1,611.00

Butterfly Network has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Butterfly Network presently has a consensus price target of $6.56, suggesting a potential downside of 16.87%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Butterfly Network had 7 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Butterfly Network and 1 mentions for Delcath Systems. Butterfly Network's average media sentiment score of 0.50 beat Delcath Systems' score of -0.07 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Delcath Systems beats Butterfly Network on 11 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

NovoCure currently has a consensus target price of $21.20, indicating a potential upside of 27.02%. Delcath Systems has a consensus target price of $23.17, indicating a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

NovoCure has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Delcath Systems	0.56%	0.46%	0.42%

Delcath Systems has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A
Delcath Systems	$85.23M	6.56	$2.70M	$0.01	1,611.00

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 6.6% of NovoCure shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NovoCure had 3 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for NovoCure and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of -0.07 beat NovoCure's score of -0.27 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Delcath Systems beats NovoCure on 13 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

LeMaitre Vascular has higher revenue and earnings than Delcath Systems. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.23	$57.73M	$2.85	27.67
Delcath Systems	$85.23M	6.56	$2.70M	$0.01	1,611.00

LeMaitre Vascular has a net margin of 25.02% compared to Delcath Systems' net margin of 0.56%. LeMaitre Vascular's return on equity of 15.63% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
Delcath Systems	0.56%	0.46%	0.42%

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular presently has a consensus target price of $110.60, suggesting a potential upside of 40.23%. Delcath Systems has a consensus target price of $23.17, suggesting a potential upside of 43.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.63 beat Delcath Systems' score of -0.07 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Summary

LeMaitre Vascular beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$563.85M	$5.50B	$7.25B	$13.14B
Dividend Yield	N/A	1.79%	2.57%	12.30%
P/E Ratio	1,612.61	25.34	275.79	25.40
Price / Sales	6.56	72.24	695.58	114.44
Price / Cash	310.86	32.72	77.42	51.66
Price / Book	5.11	5.69	10.46	6.33
Net Income	$2.70M	$151.55M	$3.49B	$358.33M
7 Day Performance	1.26%	0.66%	0.59%	1.12%
1 Month Performance	-6.06%	-3.83%	-2.01%	-2.67%
1 Year Performance	39.60%	6.86%	18.09%	6.01%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	2.7392 of 5 stars	$16.11 -0.9%	$23.17 +43.8%	+37.1%	$563.85M	$85.23M	1,612.61	156
INSP Inspire Medical Systems	3.2448 of 5 stars	$75.07 +1.0%	$66.50 -11.4%	-7.9%	$2.17B	$911.98M	16.22	1,333	Positive News
ESTA Establishment Labs	2.8833 of 5 stars	$71.70 -0.3%	$100.25 +39.8%	+70.9%	$2.13B	$245.82M	N/A	1,004	Positive News
BFLY Butterfly Network	1.3448 of 5 stars	$7.70 +3.8%	$6.56 -14.7%	+316.6%	$2.05B	$112.14M	N/A	220	Options Volume
NVCR NovoCure	2.3369 of 5 stars	$16.43 +1.3%	$21.20 +29.1%	+28.4%	$1.91B	$655.35M	N/A	1,605	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. INSP, ESTA, BFLY, NVCR, and LMAT

How does Delcath Systems compare to Inspire Medical Systems?

Summary

How does Delcath Systems compare to Establishment Labs?

Summary

How does Delcath Systems compare to Butterfly Network?

Summary

How does Delcath Systems compare to NovoCure?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. INSP, ESTA, BFLY, NVCR, and LMAT

How does Delcath Systems compare to Inspire Medical Systems?

Do insiders & institutionals believe in INSP or DCTH?

Which has higher valuation & earnings, INSP or DCTH?

Is INSP or DCTH more profitable?

Which has more volatility & risk, INSP or DCTH?

Do analysts rate INSP or DCTH?

Does the media prefer INSP or DCTH?

Summary

How does Delcath Systems compare to Establishment Labs?

Is ESTA or DCTH more profitable?

Which has stronger valuation and earnings, ESTA or DCTH?

Do insiders & institutionals hold more shares of ESTA or DCTH?

Does the media prefer ESTA or DCTH?

Which has more volatility and risk, ESTA or DCTH?

Do analysts prefer ESTA or DCTH?

Summary

How does Delcath Systems compare to Butterfly Network?

Is BFLY or DCTH more profitable?

Which has stronger earnings & valuation, BFLY or DCTH?

Which has more volatility & risk, BFLY or DCTH?

Do analysts prefer BFLY or DCTH?

Does the media favor BFLY or DCTH?

Do insiders and institutionals have more ownership in BFLY or DCTH?

Summary

How does Delcath Systems compare to NovoCure?

Do analysts rate NVCR or DCTH?

Which has more risk & volatility, NVCR or DCTH?

Is NVCR or DCTH more profitable?

Which has higher valuation and earnings, NVCR or DCTH?

Do insiders and institutionals have more ownership in NVCR or DCTH?

Does the media favor NVCR or DCTH?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Which has preferable valuation and earnings, LMAT or DCTH?

Is LMAT or DCTH more profitable?

Do insiders & institutionals believe in LMAT or DCTH?

Do analysts rate LMAT or DCTH?

Does the media favor LMAT or DCTH?

Which has more risk and volatility, LMAT or DCTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools